Precision Drugs are Needed for Precision Medicine to Work.
It was further suggested that the next 15 or 20 years would witness a complete transformation in therapeutic medicine. The promise of precision medicine is to improve patient care through therapies specifically designed to match the individual’s disease conditions and even to prevent diseases. As we enter 2023, there is little evidence available of a complete transformation in therapeutic medicine. How the goals of PM could be achieved has not yet been defined.
However, the concept, design, and availability of PDs are rarely considered. The rationale for and the approach to developing PDs have been discussed previously. The molecular structure of PDs needs to be defined and shown to interact with a precisely defined disease target with the appropriate pharmacokinetics to be efficacious.
However, some progress has been made by using targeted therapies to treat specific types of cancer cells, such as human epidermal growth factor receptor 2 -positive breast cancer cells, or using tumor marker testing to help diagnose cancer. Targeted therapies use drugs to attack specific cancer cells.
The antibodies kill the cancer cells, block their growth, or keep them from spreading. Rituximab, ofatumumab and obinutuzumab alone or combined with chemotherapy are used to treat symptomatic or progressive, recurrent, or refractory, an indefinite article targeting cluster of differentiate, a protein found on the surface of B-lymphocytes. Incidentally, accuracy and precision are both used to measure results.
Accuracy measures how close results are to the true or known value. Precision, however, measures how close results are to one another. So, perhaps we should be talking about “accuracy” medicines and drugs.
Cancer Stud Mol Med Open J. 2023; 8(1): 1-3. doi: 10.17140/CSMMOJ-8-134
